Farmako GmbH, GDP-certified pharmaceutical wholesaler with focus on cannabinoid therapy, starts the supply of THC test kits to STADAPHARM GmbH. The THC test kits developed and produced by Farmako will be offered by STADAPHARM from April 2021. They serve pharmacies as a tool for simple, fast and cost-effective identity testing of medicinal cannabis flowers and extracts.
Farmako and STADAPHARM have signed a contract for the supply of THC test kits. STADAPHARM GmbH is responsible for the distribution of special pharmaceuticals within the STADA Group and will enter the medical cannabis market from Q2 2021. The company is launching THC-containing cannabis flowers and extracts on the market for the first time and will also offer the THC test kit developed and produced by Farmako together with its new products for pharmacies for identity testing.
Farmako has been supplying the THC test kit to pharmacies as a 5-pack since December 2020. Farmako's patented THC test kit enables THC identity testing in just a few minutes, without the need for further aids or expensive reference substances. Thus, it offers an uncomplicated, fast and cost-effective alternative to the time-consuming and expensive thin-layer chromatography for the identity testing of THC-containing active ingredients or prescription drugs. The THC test kit has been validated with regard to the specificity for the detection of the identity of cannabis flowers and extracts by the testing laboratory DSI-pharm, Quality Services International GmbH.
Farmako has already been active as a reliable supplier of medicinal cannabis flowers since the beginning of 2019. In Q4 2020, the product portfolio was expanded to include CBD isolate as an active ingredient in pharmaceutical grade (GMP) as well as the THC test kit and IMC cannabis flowers. As of Q2 2021, Farmako will again expand the product portfolio to include its own THC-containing full cannabis extracts.
Farmako is thus positioning itself as a provider of a holistic portfolio in the medicinal cannabis market and continues to present itself as a reliable partner for retailers and wholesalers.
"In the cannabis market, the discussion often revolves around the high hurdles for patients, suppliers, doctors and pharmacists. Therefore, we as Farmako would like to enable or facilitate the way to a cannabinoid therapy for patients with a high burden of complaints via fair prices, reliability and efficient assistance for professionals. For us, cooperations are an important element of competition; only in this way can we all further develop the market for the benefit of the patients. We are therefore very pleased that we were able to win STADAPHARM, a renowned pharmaceutical company, as a partner," says Katrin Eckmans, Managing Director of Farmako GmbH.
Further information about the THC test kit:
According to Section 11 of the Pharmacy Operations Regulations (ApBetrO), starting materials whose quality has been verified by a test certificate must at least be tested for identity in the pharmacy. According to § 6 paragraph 1 sentence 2 ApBetrO, a pharmacy may apply other methods and use other devices than those described in the DAB for this identity test (according to DAB "Adjusted cannabis extract" as well as DAB "Cannabis flowers" this is thin layer chromatography), provided that the same results as with the described methods and devices are achieved.
Thin layer chromatography (DC) as a method for identity testing according to the DAB is effective, but involves an enormous amount of time, work and disproportionate costs. Also, the test strips available on the market so far do not provide efficient relief, as pharmacies have to elaborately produce their own testing solution for this purpose and also consume a lot of the actual cannabis material for testing - this causes increased costs for pharmacies and patients.
With the THC test kit developed and patented by Farmako, a very fast, validated and economical THC identity test is now possible, without much time and material expenditure.
The test method is based on a highly specific immunoassay THC test strip and a prepared test solution (contains methanol). All necessary test materials are already included in the test kit - only water needs to be added. Furthermore, for the qualitative detection of THC, only very little flower material (5-20mg) or extract (1-2 drops) is necessary. Already after 5 minutes the result can be read.
The supervision of pharmacies with regard to the interpretation of the DAB is the responsibility of the responsible official pharmacists or pharmacists. Since there is no nationwide uniform regulation or interpretation, pharmacists should coordinate with the responsible official pharmacists or pharmacists regarding the identity check of cannabis.
The THC test kit is protected by patent (German patent application DE102020127871).
THC test kit for pharmacists, not for distribution to end users.
Product contains methanol (Hazardous substance EC No: 200-659-6); CLP hazard class and category:
Flam. Liq. 2, Acute Tox. 3/3/3 (oral/dermal/inhalation), STOT SE 1. H225 + H301 + H311 + H331 + H370.
Please observe the safety data sheet. Dispose of hazardous materials and containers properly.
As a GDP-certified pharmaceutical wholesaler with a focus on medicinal cannabis, Farmako aims to provide reliable cannabinoid therapy to all patients with a high burden of symptoms, as well as to support doctors and pharmacists in their daily work in the best possible way: through fair prices, reliable product quality and delivery capability, and efficient service. The company has already been distributing medical cannabis products to pharmacies in Germany since March 2019 and also has the necessary licenses in the UK to start active distribution there in 2021. Farmako is a 100% subsidiary of AgraFlora Organics International Inc.
More information at: www.farmako.de
About STADA Arzneimittel AG
STADA Arzneimittel AG is headquartered in Bad Vilbel, Hesse. The company focuses on generics, including special generics, and non-prescription consumer healthcare products. STADA Arzneimittel AG sells its products in around 120 countries worldwide. In fiscal year 2020, STADA achieved Group sales of €3,010.3 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of €713.3 million. As of December 31, 2020, STADA employed 12,301 people worldwide.
More information at: www.stada.com/de
AgraFlora Organics International Inc. is a leading cannabis company focused on revenue-generating operating businesses in the global cannabis industry. AgraFlora operates primarily in Canada, the global leader in regulated and liberalized cannabis. AgraFlora Group's flagship project in Canada is Propagation Services Canada in Delta, BC, one of the largest cannabis greenhouse facilities focused on the cost-optimized cultivation of highly potent cannabis; Farmako GmbH, GDP-certified wholesaler based in Frankfurt, has already been a reliable supplier of medical cannabis in Germany since 2019 and will further expand its European presence in 2021.
More information at: https://agraflora.ca
Press contact: firstname.lastname@example.org